ECSP034838A - Inmunoconjugados del anticuerpo cd44 citotoxico - Google Patents
Inmunoconjugados del anticuerpo cd44 citotoxicoInfo
- Publication number
- ECSP034838A ECSP034838A EC2003004838A ECSP034838A ECSP034838A EC SP034838 A ECSP034838 A EC SP034838A EC 2003004838 A EC2003004838 A EC 2003004838A EC SP034838 A ECSP034838 A EC SP034838A EC SP034838 A ECSP034838 A EC SP034838A
- Authority
- EC
- Ecuador
- Prior art keywords
- antibody
- conjugates
- maitansinoid
- immunoconjugados
- citotoxic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención relacionada con conjugados novedosos de anticuerpos con compuestos citotóxicos, composiciones farmacéuticas conteniendo dichos conjugados y sus usos en la terapia para el cáncer. En particular, la presente invención relaciona a conjugados de anticuerpos que son específicos para CD44 con maitansinoide, preferentemente con N2 -deacetil- N2 (3-mercapto-1-oxopropil)-maitansina (DM1). En la incorporación particular preferida, los conjugados de anticuerpos/maitansinoide pueden ser preparados de un maitansinoide de la fórmula (II) donde R1 representa H o SR4 donde R4 representa metil, eti, alquil linear, alquil ramificado, alquil ciclic, aril sustituido o simple o heterociclic; R2 representa CI o H; R3 representa H o CH3; y m representa 1, 2 o 3. Preferentemente R1 es H o CH3, R2 es CI, R3 es CH3 y m=2. Los compuestos con R1 = H, R2 = CI, R3= CH3 y m=2 está designado DMI en la literatura
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01112237 | 2001-05-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP034838A true ECSP034838A (es) | 2003-12-24 |
Family
ID=33442672
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2003004838A ECSP034838A (es) | 2001-05-18 | 2003-11-10 | Inmunoconjugados del anticuerpo cd44 citotoxico |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1397387A1 (es) |
JP (1) | JP2005504517A (es) |
CN (1) | CN1541226A (es) |
AR (1) | AR036154A1 (es) |
BR (1) | BR0210905A (es) |
CA (1) | CA2443437A1 (es) |
CZ (1) | CZ20033476A3 (es) |
EA (1) | EA200301169A1 (es) |
EC (1) | ECSP034838A (es) |
EE (1) | EE200300569A (es) |
HU (1) | HUP0400030A3 (es) |
MX (1) | MXPA03010523A (es) |
PE (1) | PE20021098A1 (es) |
PL (1) | PL365735A1 (es) |
SK (1) | SK15592003A3 (es) |
WO (1) | WO2002094879A1 (es) |
YU (1) | YU91403A (es) |
ZA (1) | ZA200307365B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7189397B2 (en) | 1999-10-08 | 2007-03-13 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US7947496B2 (en) | 1999-10-08 | 2011-05-24 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US8071072B2 (en) | 1999-10-08 | 2011-12-06 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US8048416B2 (en) | 1999-10-08 | 2011-11-01 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US20050100542A1 (en) | 1999-10-08 | 2005-05-12 | Young David S. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
EP2316857A1 (en) * | 2004-02-12 | 2011-05-04 | Morphotek, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
WO2006099141A2 (en) | 2005-03-10 | 2006-09-21 | Morphotek, Inc. | Anti-mesothelin antibodies |
JP2009521206A (ja) | 2005-04-22 | 2009-06-04 | モルフォテック、インク. | 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体 |
WO2008157369A2 (en) * | 2007-06-13 | 2008-12-24 | Zymogenetics, Inc. | Use of taci-ig fusion protein such as atacicept for the manufacture of a medicament for treating lupus erythematosus |
EP2009028A1 (en) * | 2007-06-27 | 2008-12-31 | Monoclonal Antibodies Therapeutics | Combination of a conventional anti-cancer treatment with anti-CD44 antibody administration for treating solid tumors |
CA2786337A1 (en) | 2010-02-04 | 2011-08-11 | F. Hoffmann-La Roche Ag | A monoclonal antibody to cd44 for use in the treatment of head and neck squamous cell carcinoma |
CN102337298B (zh) * | 2011-08-19 | 2013-11-06 | 黄开红 | 一种输送siRNA的免疫纳米载体及其制备方法和应用 |
EP2788024A1 (en) | 2011-12-06 | 2014-10-15 | F.Hoffmann-La Roche Ag | Antibody formulation |
WO2017215637A1 (zh) * | 2016-06-15 | 2017-12-21 | 李翀 | 一种人子宫内膜癌的标志物、抗体及其应用 |
CN107556388A (zh) * | 2016-06-30 | 2018-01-09 | 中国科学院深圳先进技术研究院 | 抗CD44v6和CD3特异性双靶向抗体、含该双靶向抗体表达盒的微环DNA及应用 |
JP2024512324A (ja) * | 2021-03-05 | 2024-03-19 | ジーオー セラピューティクス,インコーポレイテッド | 抗グリコcd44抗体およびその使用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0438310A1 (en) * | 1990-01-19 | 1991-07-24 | Merck & Co. Inc. | Method for producing recombinant immunoglobuline |
GB9020282D0 (en) * | 1990-09-17 | 1990-10-31 | Gorman Scott D | Altered antibodies and their preparation |
CA2149635A1 (en) * | 1992-11-20 | 1994-06-09 | David Tarin | Peptide corresponding to cd44 exon 6, antibodies specific for said peptide and use of these antibodies for diagnosis of tumors |
UA58482C2 (uk) * | 1994-06-08 | 2003-08-15 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти |
UY24389A1 (es) * | 1995-12-06 | 2001-10-25 | Karlsruhe Forschzent | Composición farmacéutica para el tratamiento de carcinoma de epitelio plano |
-
2002
- 2002-05-17 EE EEP200300569A patent/EE200300569A/xx unknown
- 2002-05-17 WO PCT/EP2002/005467 patent/WO2002094879A1/en not_active Application Discontinuation
- 2002-05-17 CA CA002443437A patent/CA2443437A1/en not_active Abandoned
- 2002-05-17 MX MXPA03010523A patent/MXPA03010523A/es unknown
- 2002-05-17 AR ARP020101830A patent/AR036154A1/es not_active Suspension/Interruption
- 2002-05-17 YU YU91403A patent/YU91403A/sh unknown
- 2002-05-17 PL PL02365735A patent/PL365735A1/xx not_active Application Discontinuation
- 2002-05-17 HU HU0400030A patent/HUP0400030A3/hu unknown
- 2002-05-17 EP EP02735364A patent/EP1397387A1/en not_active Ceased
- 2002-05-17 EA EA200301169A patent/EA200301169A1/ru unknown
- 2002-05-17 CN CNA028101561A patent/CN1541226A/zh active Pending
- 2002-05-17 JP JP2002592353A patent/JP2005504517A/ja active Pending
- 2002-05-17 CZ CZ20033476A patent/CZ20033476A3/cs unknown
- 2002-05-17 SK SK1559-2003A patent/SK15592003A3/sk not_active Application Discontinuation
- 2002-05-17 PE PE2002000422A patent/PE20021098A1/es not_active Application Discontinuation
- 2002-05-17 BR BR0210905-0A patent/BR0210905A/pt not_active Expired - Fee Related
-
2003
- 2003-09-22 ZA ZA200307365A patent/ZA200307365B/xx unknown
- 2003-11-10 EC EC2003004838A patent/ECSP034838A/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2002094879A1 (en) | 2002-11-28 |
HUP0400030A3 (en) | 2006-02-28 |
CA2443437A1 (en) | 2002-11-28 |
ZA200307365B (en) | 2004-05-10 |
MXPA03010523A (es) | 2004-07-01 |
EP1397387A1 (en) | 2004-03-17 |
YU91403A (sh) | 2006-05-25 |
EA200301169A1 (ru) | 2004-06-24 |
BR0210905A (pt) | 2004-06-08 |
PL365735A1 (en) | 2005-01-10 |
JP2005504517A (ja) | 2005-02-17 |
SK15592003A3 (sk) | 2004-06-08 |
AR036154A1 (es) | 2004-08-18 |
CN1541226A (zh) | 2004-10-27 |
HUP0400030A2 (hu) | 2004-04-28 |
CZ20033476A3 (cs) | 2004-05-12 |
PE20021098A1 (es) | 2003-02-11 |
EE200300569A (et) | 2004-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP034838A (es) | Inmunoconjugados del anticuerpo cd44 citotoxico | |
AR018634A1 (es) | Derivados de benzo(b)tiepin-1,1,-dioxido, procedimiento para su preparacion, medicamentos conteniendo estos compuestos, procedimiento para la preparacion de medicamentos y su empleo para la preparacion de medicamentos. | |
AR012315A1 (es) | Derivados de ditiolan y el uso de los mismos en la fabricacion de un medicamento. | |
ES2012809B3 (es) | Derivados del taxol, su preparacion y composiciones farmaceuticas que los contienen. | |
AR033499A1 (es) | Derivado de quinazolina, proceso para su preparacion, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para usar en la produccion de un efecto antiangeogenico y/o reductor de la permeabilidad vascular en un animal de sangre caliente | |
ES2054860T5 (es) | Derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion y su utilizacion como medicamentos. | |
AR065937A2 (es) | Compuesto derivado indazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de medicamentos para modular la actividad de proteina quinasa | |
ES2176480T3 (es) | Derivados acilados de la melatonina y de analogos como medicamentos. | |
AR004219A1 (es) | Nuevos derivados de quinazolina, procedimientos para su preparacion, composiciones que los contienen y su uso en la preparacion de medicamentos,particularmente en el tratamiento de trastornos inflamatorios | |
MX9305769A (es) | Nuevos derivados de analogos del taxol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
SV1999000118A (es) | Nuevos derivados de pirazol substituidos ref. lea 33188-sv | |
ECSP034831A (es) | Derivados sustituidos de la 2-piridina ciclohexano-1,4-diamina | |
MXPA03010432A (es) | Inmunoconjugados del anticuerpo cd44 citotoxico. | |
AR030279A1 (es) | Derivados de fenilamida para-amino sustituida activadora de la glucoquinasa, un procedimiento para su preparacion, composiciones farmaceuticas y el empleo de dichos derivados para la preparacion de medicamentos. | |
CY1116183T1 (el) | Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης | |
CL2021003594A1 (es) | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos. | |
AR009572A1 (es) | Derivados de 3,4,5,6,7,8-hexahidro pirido (4',3':4,5) tieno (2,3-d) pirimidina sustituidos en posicion 3 y su uso | |
CO5040004A1 (es) | 2-4-diamino-1,3,5-triazinas, su preparacion y empleo como herbicidas y fitorreguladores | |
ES2191029T3 (es) | Derivados de taxano c7 y composiciones farmaceuticas que los contienen. | |
FI803264L (fi) | 2-hydroxialkyl-3,4,5-trihydroxipiperidiner foerfarande foer framstaellning av dem och anvaendning av dem som laekemedel | |
AR018619A1 (es) | Derivados de 8-fenilxantina utiles como inhibidores de fosfoestearasa gmp ciclica (pdes), preparacion, composiciones farmaceuticas formuladas con dichosderivados y uso de dichos derivados para la fabricacion de medicamentos | |
AR043487A1 (es) | Heterociclos fusionados de pirimidina y usos de los mismos | |
MX9203712A (es) | Derivados de benzanilida y composiciones farmaceuticas que los contienen. | |
ATE13423T1 (de) | Guanidinderivate und diese enthaltende pharmazeutische zusammensetzungen. | |
AR004484A1 (es) | Nuevas 1,2,3,4-tetrahidro-2-naftalenaminas fenilo-sustituidas en el anillo aromatico, su preparacion, sus aplicaciones terapeuticas y las composicionesfarmaceuticas que las contienen. |